Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CRNX Stock Summary
Top 10 Correlated ETFs
CRNX
In the News

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023.

Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
Crinetics Pharmaceuticals' lead candidate could be commercialized soon. It'll have a hard time gaining market share quickly if it gets approved for sale.

Why Crinetics Pharmaceuticals Stock Soared This Week
Crinetics Pharmaceuticals announced positive late-stage trial data for its acromegaly drug this week. If approved, analysts think this oral therapy could rake in nearly half a billion in annual sales at peak.

Why Shares of Crinetics Pharmaceuticals Are Jumping Monday
Crinetics focuses on treatments for rare endocrine-related diseases and cancers. The company had only $264.5 million in cash as of the second quarter.

Pharma Stock Eyes Best Day Ever on Successful Trial
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock is surging today, last seen up 72.7% to trade at $27.58 at last check, after the late stage trial for its experimental drug paltusotine to treat a rare hormonal disorder was successful.

Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today?
Crinetics Pharmaceuticals (NASDAQ: CRNX ) stock is on the rise Monday after the company announced positive clinical trial results. According to a press release from the company, its Phase 3 PATHFNDR-1 clinical trial was able to meet all of its primary and secondary endpoints.

Crinetics Pharmaceuticals shares surge 65%, analysts raise price target after acromegaly treatment results
Shares of Crinetics Pharmaceuticals Inc. CRNX, -1.18% gained 65% premarket on Monday after the company announced positive results from a late-stage study of paltusotine, its investigational treatment for acromegaly. The phase 3 trial met the primary endpoint and all secondary endpoints and no serious or severe adverse events were reported in patients receiving paltusotine for acromegaly, a rare disease that occurs when the body produces too much growth hormone.

Crinetics Pharmaceuticals shares rise as analysts see ‘drug hunters in their zone'
Shares of Crinetics Pharmaceuticals Inc. CRNX, gained more than 4% premarket on Thursday after Oppenheimer analysts initiated coverage of the shares with an outperform rating, calling Crinetics ‘drug hunters in their zone.' Crinetics focuses on developing treatments for rare endocrine diseaess, an area where current drugs' risk-benefit tradeoffs “leave much room for improvement, or approved options are outright lacking,” the analysts wrote in a note Wednesday.

Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly
Crinetics Pharmaceuticals, Inc. is my latest long position. The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current treatments have side effects.

Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO
Crinetics Pharmaceuticals has shown a significant increase in R&D and administrative expenses, leading to a widening net loss trajectory. The company's primary revenue source is the drug paltusotine, which has shown promising results in the treatment of acromegaly. Crinetics has a robust product pipeline, including potential treatments for Cushing's disease and neuroendocrine tumors.
CRNX Financial details
CRNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.2 | 0.05 | 0 | 0.03 | 0.09 | |
Net income per share | -2.23 | -2.05 | -2.39 | -2.78 | -3.08 | |
Operating cash flow per share | -1.6 | -1.92 | -2.04 | -2.3 | -2.22 | |
Free cash flow per share | -1.69 | -1.94 | -2.04 | -2.32 | -2.25 | |
Cash per share | 13.5 | 4.9 | 5.61 | 8.68 | 6.43 | |
Book value per share | -3.57 | -3.88 | -5.5 | -7.16 | -8.45 | |
Tangible book value per share | 13.2 | 4.85 | 5.55 | 8.64 | 6.09 | |
Share holders equity per share | -3.57 | -3.88 | -5.5 | -7.16 | -8.45 | |
Interest debt per share | 0 | 0.2 | 0.13 | 0.08 | 0.12 | |
Market cap | 364.14M | 606.55M | 429.62M | 1.09B | 951.27M | |
Enterprise value | 319.17M | 571.07M | 340.55M | 894.35M | 920.62M | |
P/E ratio | -13.43 | -12.24 | -5.9 | -10.23 | -5.95 | |
Price to sales ratio | 149.97 | 508.42 | 6.05K | 1.01K | 200.82 | |
POCF ratio | -18.71 | -13.08 | -6.93 | -12.33 | -8.26 | |
PFCF ratio | -17.75 | -12.94 | -6.91 | -12.27 | -8.14 | |
P/B Ratio | -8.39 | -6.47 | -2.56 | -3.97 | -2.17 | |
PTB ratio | -8.39 | -6.47 | -2.56 | -3.97 | -2.17 | |
EV to sales | 131.45 | 478.69 | 4.8K | 829.63 | 194.35 | |
Enterprise value over EBITDA | -11.12 | -10.61 | -4.54 | -8.3 | -5.48 | |
EV to operating cash flow | -16.4 | -12.31 | -5.49 | -10.1 | -7.99 | |
EV to free cash flow | -15.56 | -12.18 | -5.47 | -10.05 | -7.88 | |
Earnings yield | -0.07 | -0.08 | -0.17 | -0.1 | -0.17 | |
Free cash flow yield | -0.06 | -0.08 | -0.14 | -0.08 | -0.12 | |
Debt to equity | 0 | -0.05 | -0.02 | -0.01 | 0 | |
Debt to assets | 0 | 0.04 | 0.02 | 0.01 | 0.01 | |
Net debt to EBITDA | 1.57 | 0.66 | 1.19 | 1.83 | 0.18 | |
Current ratio | 21.03 | 14.79 | 16.92 | 21.55 | 12.45 | |
Interest coverage | 0 | 0 | 0 | 0 | -38.89 | |
Income quality | 0.72 | 0.92 | 0.84 | 0.82 | 0.7 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.74 | 11.33 | 253.89 | 22.75 | 8.95 | |
Research and developement to revenue | 10.08 | 34.79 | 802.79 | 78.16 | 27.49 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.01 | 0 | 0 | 0.01 | |
Capex to revenue | -0.44 | -0.41 | -2.62 | -0.4 | -0.35 | |
Capex to depreciation | -2.25 | -0.55 | -0.2 | -0.47 | -1.68 | |
Stock based compensation to revenue | 0.96 | 5.28 | 146.86 | 16.1 | 5.97 | |
Graham number | 13.4 | 13.37 | 17.22 | 21.15 | 24.19 | |
ROIC | 0.7 | 0.63 | 0.46 | 0.4 | 0.38 | |
Return on tangible assets | -0.16 | -0.38 | -0.4 | -0.3 | -0.45 | |
Graham Net | 12.67 | 4.36 | 5.15 | 8.33 | 5.78 | |
Working capital | 158.76M | 115M | 167M | 328.73M | 317.46M | |
Tangible asset value | 160.23M | 117.14M | 168.92M | 331.94M | 316.33M | |
Net current asset value | 155.49M | 110.1M | 162.97M | 325.65M | 309.34M | |
Invested capital | 0 | -0.05 | -0.02 | -0.01 | 0 | |
Average receivables | 1.16M | 1.48M | 1.61M | 1.93M | 2.23M | |
Average payables | 929.5K | 3.48M | 5.54M | 7.03M | 7.68M | |
Average inventory | 70.5K | -689K | -1.61M | 3.12M | 4.04M | |
Days sales outstanding | 238.12 | 421.6 | 9.42K | 687 | 186.85 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.53 | 0.87 | 0.04 | 0.53 | 1.95 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.63 | 0.53 | 0.43 | 0.39 | 0.36 | |
Capex per share | -0.09 | -0.02 | -0.01 | -0.01 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.01 | 0.01 | 0.01 | 0.05 | 0.02 | |
Net income per share | -0.79 | -0.75 | -0.79 | -0.82 | -0.94 | |
Operating cash flow per share | -0.53 | -0.72 | -0.65 | -0.76 | -0.84 | |
Free cash flow per share | -0.54 | -0.73 | -0.66 | -0.76 | -0.85 | |
Cash per share | 7.78 | 6.85 | 6.21 | 5.49 | 4.87 | |
Book value per share | 7.35 | 6.53 | -8.16 | -9 | 4.68 | |
Tangible book value per share | 7.35 | 6.53 | 5.88 | 5.2 | 4.68 | |
Share holders equity per share | 7.35 | 6.53 | -8.16 | -9 | 4.68 | |
Interest debt per share | 0.06 | 0.09 | 0.07 | 0.02 | 0.05 | |
Market cap | 979.54M | 1.06B | 985.25M | 865.76M | 978.04M | |
Enterprise value | 919.81M | 1.03B | 954.61M | 827.39M | 941.05M | |
P/E ratio | -5.87 | -6.54 | -5.81 | -4.92 | -4.8 | |
Price to sales ratio | 2.23K | 2.31K | 1.39K | 323.17 | 989.91 | |
POCF ratio | -35.01 | -27.44 | -27.98 | -21.26 | -21.38 | |
PFCF ratio | -34.26 | -26.97 | -27.77 | -21.25 | -21.27 | |
P/B Ratio | 2.54 | 3.01 | -2.24 | -1.78 | 3.85 | |
PTB ratio | 2.54 | 3.01 | -2.24 | -1.78 | 3.85 | |
EV to sales | 2.1K | 2.25K | 1.35K | 308.84 | 952.48 | |
Enterprise value over EBITDA | -21.46 | -23.8 | -20.07 | -17.25 | -17.85 | |
EV to operating cash flow | -32.88 | -26.73 | -27.11 | -20.32 | -20.58 | |
EV to free cash flow | -32.17 | -26.26 | -26.9 | -20.31 | -20.47 | |
Earnings yield | -0.04 | -0.04 | -0.04 | -0.05 | -0.05 | |
Free cash flow yield | -0.03 | -0.04 | -0.04 | -0.05 | -0.05 | |
Debt to equity | 0.01 | 0.01 | 0 | -0.01 | 0.01 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 1.39 | 0.64 | 0.64 | 0.8 | 0.7 | |
Current ratio | 15.94 | 15.41 | 12.45 | 11.6 | 8.73 | |
Interest coverage | -59.78 | -28.97 | -24.98 | 24.19 | 0 | |
Income quality | 0.66 | 0.92 | 0.78 | 0.89 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 23.89 | 26.04 | 15.9 | 4.55 | 13.51 | |
Research and developement to revenue | 75.16 | 69.84 | 52.17 | 14.36 | 41.13 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.02 | 0.01 | 0 | 0.01 | |
Capex to revenue | -1.4 | -1.49 | -0.39 | -0.01 | -0.24 | |
Capex to depreciation | -2.85 | -2.75 | -0.98 | -0.06 | -0.85 | |
Stock based compensation to revenue | 16.24 | 16.23 | 11.21 | 3.02 | 10.3 | |
Graham number | 11.46 | 10.51 | 12.03 | 12.86 | 9.95 | |
ROIC | -0.11 | -0.12 | 0.1 | 0.1 | -0.2 | |
Return on tangible assets | -0.1 | -0.1 | -0.12 | -0.14 | -0.17 | |
Graham Net | 7.17 | 6.32 | 5.58 | 4.88 | 4.33 | |
Working capital | 390.17M | 353.77M | 317.46M | 279.08M | 252.2M | |
Tangible asset value | 386.17M | 351.37M | 316.33M | 280.33M | 254.12M | |
Net current asset value | 380.72M | 344.82M | 309.34M | 271.72M | 245.67M | |
Invested capital | 0.01 | 0.01 | 0 | -0.01 | 0.01 | |
Average receivables | 1.83M | 2.23M | 2.39M | 2.39M | 2.37M | |
Average payables | 10.59M | 7.46M | 6.38M | 6.39M | 5.37M | |
Average inventory | 4.7M | 5M | 2.98M | -1.17M | 6.39M | |
Days sales outstanding | 432.78 | 460.81 | 307.83 | 78.91 | 216.98 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.21 | 0.2 | 0.29 | 1.14 | 0.41 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.11 | -0.11 | 0.1 | 0.09 | -0.2 | |
Capex per share | -0.01 | -0.01 | -0.01 | 0 | 0 |
CRNX Frequently Asked Questions
What is Crinetics Pharmaceuticals, Inc. stock symbol ?
Crinetics Pharmaceuticals, Inc. is a US stock , located in San diego of Ca and trading under the symbol CRNX
Is Crinetics Pharmaceuticals, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $39.5. The lowest prediction is $39 and the highest is $40
What is CRNX stock prediction ?
With a median analyst target price of $40, 1 stock analysts have made 1 forecasts in last 90 days. $40 is the lowest and $40 is the greatest projection.
What is Crinetics Pharmaceuticals, Inc. stock quote today ?
Crinetics Pharmaceuticals, Inc. stock price is $29.225 today.
Is Crinetics Pharmaceuticals, Inc. stock public?
Yes, Crinetics Pharmaceuticals, Inc. is a publicly traded company.